Study Results

Viveve conducted a First in Woman clinical study (n=24) that began in November of 2008. The IRB approved Non-Significant Risk Study was conducted at The Institute for Women’s Health, West Palm Beach, Florida. All procedures were performed by Dr. Seth Herbst.The primary purpose was safety and the secondary purpose was efficacy. Our observations from the study include:

• It was safe, as there were no reported or observed adverse events
• It was well-tolerated, as no topical or general anesthetics or analgesics were required
• Significantly improved vaginal tightness scores were reported by patients at 1 month post treatment and were sustained at 3, 6 and 9 months follow-up
• Significantly improved scores for sexual satisfaction and sexual function were sustained at 3, 6, and 9 months follow- up

Viveve continues its clinical path towards commercialization. Further study results will be posted here when available.